A Combination of Thalidomide and Augmentin Protects BALB/c Mice Suffering from Klebsiella pneumoniae B5055-Induced Sepsis

REFERENCES

• Rangel-Frausto MS, Pittet D, Costigan M et al. The natural history of the systemic inflammatory response syndrome (SIRS). JAMA 1995; 273: 117–123.
   Google Scholar
• Zeigler EJ, Fisher CJ, Sprung CL et al. Treatment of gram negative bacteremia and septic shock with HA-1A human mon-oclonal antibody against endotoxin. N Engl J Med 1991; 324: 429–436.
   Google Scholar
• Anderson ID, Fearon KC, Grant LC. Laparotomy for ab-dominal sepsis in critically ill. Br J Surg 1996; 83: 1694–1697.
   Google Scholar
• Cunha BA. Antibiotic treatment of sepsis. Med Clin N Am 1995; 79: 551–558.
   PubMed Web of Science ®Google Scholar
• Roilides E, Pizzo PA. Modulation of host defenses by cy-tokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis 1992; 15: 508–524.
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachetin/TNF monoclonal antibodies prevent septic shock during lethal bac-teremia. Nature 1987; 330: 662–664.
   PubMed Web of Science ®Google Scholar
• Abraham V. Cytokine modifiers: pipe dream or reality. Chest. 1998; 113: 224S-227S.
   Google Scholar
• Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. et al. Confirmatory interlukin-1 receptor antag-onist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25: 1115-1124.
   Google Scholar
• Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Car-cillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303–1310.
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent J-L, Latter P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sep-sis. N Engl J Med 2001; 344: 699–709.
   PubMed Web of Science ®Google Scholar
• Mellin GW, Katzenstein M. The saga of thalidomide. New Engl J Med. 1962; 267: 1184–1193.
   PubMed Web of Science ®Google Scholar
• Sampaio EP, Kaplan G, Miranda A et al. The influence of thalidomide on the clinical and immunologic manifestations of erythema nodosum leprosum. J Infect Dis 1993; 168: 408–414.
   Google Scholar
• Tavares JL, Wangoo A, Diworth P, Marshall B, Kotecha S, Shawn RJ. Thalidomide reduces tumor necrosis factor-alpha production by alveolar macrophages. Respir Med 1997; 91: 31–39.
   PubMed Web of Science ®Google Scholar
• Leonard C, Alans BF. Thalidomide: Current and potential clinical applications. Am J Med 2000; 108: 487–495.
   PubMed Web of Science ®Google Scholar
• Yasui, K, Kobayashi N, Yamazaki T, Agematsu K. Thalidomide as an Immunotherapeutic agent: The effect on Neu-trophil mediated inflammation. Curr Pharma Des 2005; 11: 395–401.
   PubMed Web of Science ®Google Scholar
• Kumar V, Chhibber S. Anti-inflammatory effect of thalido-mide alone or in combination with augmentin in Klebsiella pneu-moniae B5055 induced acute lung infection in BALB/c mice. Eur J Pharmacol 2008; 592: 146–150.
   PubMed Web of Science ®Google Scholar
• DeMarsh PL, Wells GI, Lewandowski TF, Frey CL, Bhat-nagar PK, Ostovic EJR. Treatment of experimental gram-nega-tive and gram positive bacterial sepsis with the hemoregulatory peptide SK&F 107647. J Infect Dis 1996; 173: 203–211.
   PubMed Web of Science ®Google Scholar
• Toky V, Sharma S, Arora BB, Chhibber S. establishment of sepsis model following implantation of Klebsiella pneumoniae-infected fibrin clot into the peritoneal cavity of mice. Folia Mi-crobiol 2003; 48 (5): 665–669.
   PubMed Web of Science ®Google Scholar
• Ohkawa H, Ohishi N, Yagi K. Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351–358.
   PubMed Web of Science ®Google Scholar
• Tsai WC, Strieter RM, Zisman DA, Wilkowski JM, Buck-nell KA, Chen G, Standiford TJ. Nitric oxide is required for effective innate immunity against Klebsiella pneumoniae. Infect Immun 1997; 65: 1870–1875.
   PubMed Web of Science ®Google Scholar
• Zeni F, Freeman B, Natanson C. Anti-inflammatory ther-apies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25: 1095–1100.
   PubMed Web of Science ®Google Scholar
• Arndt P, Abraham E. immunological therapy of sepsis: ex-perimental therapies. Intensive Care Med 2001; 27: 104–115.
   PubMed Web of Science ®Google Scholar
• Calabrese L, Fleitscher AB Jr. Thalidomide: current and potential applications. Am J Med 2000; 108: 487–495.
   PubMed Web of Science ®Google Scholar
• Schimdt H, Rush B, Simonian G, Murphy T, Hsieh J, Condon M. Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats. J Surg Res 1996; 63: 143–146.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bouboulis EJ, Poulaki H, Kostomitsopoulos N, Dontas I, Perrea D, Karayannacos E, Giamarellou H. Effective immunomodulatory treatment of Escherichia coil experimental sepsis with thalidomide. Antimicrob Agents Chemother 2003; 47 (8): 2445–2449.
   PubMed Web of Science ®Google Scholar
• Bala S, Hastings KL, Kazempour K, Inglis S, Dempsey WL. Inhibition of tumor necrosis factor-alpha alters resistance to Mycobacterium avium complex infection in mice. Antimicrob Agents Chemother 1998; 42: 2336–2341.
   PubMed Web of Science ®Google Scholar
• Tadesse A, Shannon EJ. Effect of thalidomide in intracel-lular Mycobacterium leprae in normal and activated macrophages. Clin Diag Lab Immunol 2005; 12: 130–134.
   PubMedGoogle Scholar
• Giamarellos-Bouboulis EJ, Bolanos N, Laoutaris G, et al. Immunomodulatory intervaention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study. BMC Infectious disease 2005; 5: 51–56.
   PubMed Web of Science ®Google Scholar
• Schimtz N, Kurrer M, Bachmann MF, Kopf M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol 2005; 79 (10): 6441–6448.
   PubMed Web of Science ®Google Scholar
• Tamaoki J. The effects of macrolides on inflammatory cells. CHEST 2004; 125: 41S-51S.
   Google Scholar
• Tsenova L, Sokol K, Freedman VH, Kaplan G. A combination of thalidomide and antibiotics protects rabbits from my-cobacterial meningitis-associated death. J Infect Dis 1998; 177: 1563–1572.
   PubMed Web of Science ®Google Scholar
• Giuseppe M, Emanuela M, Tiziana G, Rosanna Di P, Carmelo M, Concetta C, et al. Effects of thalidomide in cerulein-induced acute pancreatitis. Shock 2008; 29 (1): 89–97.
   PubMed Web of Science ®Google Scholar